CRISPR Therapeutics' Zugo-cel (CTX112): Next-Gen CAR-T Advances in Phase 1/2

Last updated July 24, 2026: This article originally described a “September 12 PDUFA date” and “October 10 AdCom” for CTX112. These dates appear to be incorrect — no BLA has been filed for CTX112 (now renamed zugocabtagene geleucel, or zugo-cel). The program remains in Phase 1/2 trials in both hematologic malignancies and autoimmune diseases. The article has been rewritten to reflect the actual development status.

CRISPR Therapeutics’ zugocabtagene geleucel (zugo-cel; formerly CTX112) is the company’s next-generation allogeneic CAR-T cell therapy, in development for both B-cell malignancies and autoimmune diseases. It has not yet reached a PDUFA date — no BLA has been filed.

The drug

Zugo-cel is a next-generation allogeneic CAR-T cell therapy targeting CD19. It uses CRISPR gene editing to knock out three genes (TRAC, B2M, PD-1) that limit CAR-T function, and knocks in a CD19-targeting CAR and a HLA-E shield to protect the cells from immune rejection.

In plain English: it’s a more durable, more potent version of first-gen CAR-T, engineered to last longer in the body and resist the tumor’s attempts to shut it down. The “off-the-shelf” (allogeneic) approach doesn’t require collecting the patient’s own cells.

The data

The Phase 1 trial in 32 patients with relapsed/refractory B-cell malignancies showed:

• Overall response rate (ORR): 69%
• Complete response (CR): 59%
• 6-month durability: 82% of CR patients remained in remission at 6 months

The safety profile was manageable: cytokine release syndrome (CRS) in 22% (all Grade 1-2), no Grade 3+ neurotoxicity. No dose-limiting toxicities.

The FDA granted Fast Track designation based on this data.

Expansion into autoimmune disease

In December 2025, CRISPR Therapeutics announced a broad update on zugo-cel, highlighting expansion into autoimmune diseases. The company is running a Phase 1 basket trial in autoimmune rheumatologic diseases, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis. This mirrors the broader industry trend of using CD19 CAR-T to deplete autoreactive B cells in autoimmune conditions.

CRISPR also established a collaboration with Lilly to evaluate zugo-cel together with pirtobrutinib in aggressive B-cell lymphomas, expanding the program’s development in oncology.

The market

CAR-T cell therapies are a $5 billion market, growing 20%+ per year. Current leaders:

• Gilead (Yescarta): ~$1.5B revenue, CD19 CAR-T for lymphoma
• Novartis (Kymriah): ~$0.5B revenue, CD19 CAR-T for leukemia/lymphoma
• J&J/BMS (Carvykti): ~$1B revenue, BCMA CAR-T for myeloma

Zugo-cel enters the CD19 CAR-T market, competing with Yescarta and Kymriah. The differentiator: enhanced potency from CRISPR editing, potentially better durability, and an “off-the-shelf” (allogeneic) manufacturing approach that doesn’t require collecting the patient’s own cells.

If approved, peak sales estimates range from $500M–$1.5B. CRISPR Therapeutics’ market cap is approximately $2.4 billion (at $47.53 per share on July 24, 2026), driven by Casgevy (sickle cell) and the broader pipeline.

What we’re watching

1. Phase 1/2 advancement: Zugo-cel is still in Phase 1/2. No BLA has been filed. The next milestone is larger trial enrollment and potential advancement to Phase 2/3.
2. Autoimmune data: The Phase 1 basket trial in autoimmune diseases (SLE, SSc, inflammatory myositis) could open a significant new market. Data updates are expected in 2026.
3. Lilly collaboration: The combination with pirtobrutinib in aggressive B-cell lymphomas could expand the oncology opportunity.
4. Manufacturing consistency: The allogeneic platform’s manufacturing consistency will be a key regulatory question when a BLA is eventually filed.

CRISPR Therapeutics is building a multi-product company on the gene-editing platform. Zugo-cel is the second program, but it is earlier in development than originally described. The autoimmune expansion is the most interesting new development.